Lipocine Inc. — Q3 2016 Form 10-Q
Business context and period: Unaudited results for the three and nine months ended September 30, 2016. Lipocine is a clinical-stage specialty pharmaceutical company developing oral drug-delivery products for men’s and women’s health. It had no product sales revenue and reported no revenue in the presented operating statements.
Financial results and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Research and development expense | $1.51 million | $4.73 million | $6.75 million | $9.81 million |
| General and administrative expense | $1.39 million | $1.70 million | $9.04 million | $3.87 million |
| Restructuring costs | $0.39 million | — | $0.39 million | — |
| Operating loss | $(3.29) million | $(6.43) million | $(16.17) million | $(13.69) million |
| Net loss | $(3.24) million | $(6.37) million | $(16.01) million | $(13.57) million |
| Basic and diluted loss per share | $(0.18) | $(0.35) | $(0.88) | $(0.86) |
| Cash used in operating activities | Not stated separately | Not stated separately | $(15.73) million | $(12.44) million |
At September 30, 2016, cash and cash equivalents were $4.71 million and marketable securities were $24.13 million, totaling approximately $28.84 million in cash and investments. Total assets were $29.55 million; total liabilities were $1.57 million, all current. The balance sheet reports no debt. Accumulated deficit was $102.45 million. No meaningful operating margin is presented because the company had no product revenue.
Changes and notable items
- Q3 net loss narrowed year over year, mainly reflecting lower R&D spending, including the absence of the $2.3 million 2015 FDA NDA filing fee and lower contract research costs. These savings were partly offset by higher LPCN 1021 validation and manufacturing costs.
- Nine-month net loss increased year over year. G&A rose $5.17 million, with management citing increased LPCN 1021 pre-commercialization spending, personnel costs, salaries and stock-based compensation. Nine-month stock-based compensation was $1.93 million versus $0.74 million.
- Operating cash use increased by $3.29 million year over year. Investing activities provided $0.40 million, principally reflecting maturities of marketable securities; financing provided $0.03 million, versus $32.72 million in 2015, which included the April 2015 stock offering.
- In July 2016, Lipocine eliminated eight positions, approximately 33% of its workforce, and recorded $0.39 million in restructuring expense. After the October FDA meeting, it eliminated two more positions and estimated about $0.34 million of related cash costs, to be recognized in Q4.
Outlook, development and risks
- LPCN 1021: The FDA issued a Complete Response Letter on June 28, 2016, citing issues with the proposed label dosing algorithm and its difference from the Phase 3 trial titration scheme. After an October 6 Post Action meeting, the FDA indicated that the proposed regimen might be acceptable but required validation in a clinical trial before resubmission. Lipocine submitted a study protocol for Special Protocol Assessment review in October. Management estimated about $5.0 million in additional LPCN 1021 R&D costs and anticipated delay to any launch; approval is not assured.
- Other candidates: LPCN 1111 completed a Phase 2b dose-finding study; management reported that the target Phase 3 dose met primary and secondary endpoints and planned an FDA discussion on the Phase 3 path in Q4 2016. LPCN 1107 completed a Phase 2 dose-selection study and an End-of-Phase-2 meeting; FDA feedback on Phase 3 design was expected in Q1 2017. These are management expectations stated in the filing, not confirmed outcomes.
- Funding: Management believed available resources would fund projected requirements for at least 12 months, through September 30, 2017, but said additional capital would be needed at some point. The company had no credit facility or committed funding sources. Financing may be unavailable or require dilution, unfavorable terms, reduced development, or other strategic concessions.
- Operating outlook: Lipocine expected continued losses and significant expenses. It expected R&D costs to decline until additional trials begin, while spending and capital needs remain sensitive to clinical design, FDA decisions, manufacturing, and commercialization plans.
- Contingencies and other matters: The Clarus patent-infringement lawsuit was dismissed by the Delaware District Court on October 6, 2016, while a related patent interference proceeding remained pending. Shareholder securities lawsuits were pending; the company disputed the claims and reported no accrued contingency. Management said the ultimate outcomes of legal matters could not be estimated, but did not expect a material adverse effect based on information then available.
Investor verification points
- Check FDA feedback on the LPCN 1021 dosing-validation protocol, trial requirements, timing, cost and any resubmission pathway.
- Reassess cash burn and runway against the $28.84 million cash-and-investments balance, management’s September 2017 funding horizon and expected clinical costs.
- Track LPCN 1111 and LPCN 1107 FDA discussions and whether planned development milestones were achieved.
- Review the effects of workforce reductions on development execution and the estimated Q4 restructuring charge.
- Monitor the patent interference and shareholder litigation, including potential costs and any changes to management’s assessment.